PROGNOSTIC FACTORS IN MULTIPLE MYELOMA

Hematology/Oncology Clinics of North America 13, 1295-1314 DOI: 10.1016/s0889-8588(05)70128-3

Citation Report

#	Article	IF	CITATIONS
1	Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplantation, 2000, 26, 979-983.	2.4	55
2	Immunophenotypic Aberrations, DNA Content, and Cell Cycle Analysis of Plasma Cells in Patients with Myeloma and Monoclonal Gammopathies. Blood Cells, Molecules, and Diseases, 2000, 26, 634-645.	1.4	33
3	Recurring chromosomal abnormalities in non-hodgkin's lymphoma: Biologic and clinical significance. Seminars in Hematology, 2000, 37, 396-411.	3.4	71
5	A high bone marrow plasma cell labeling index in stable plateau–phase multiple myeloma is a marker for early disease progression and death. Blood, 2001, 97, 2522-2523.	1.4	50
6	Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood, 2001, 98, 23-28.	1.4	94
7	Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Annals of Hematology, 2001, 80, 393-397.	1.8	25
8	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Seminars in Oncology, 2001, 28, 620-625.	2.2	96
9	CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma. Leukemia Research, 2001, 25, 1051-1057.	0.8	30
10	Multiple Myeloma: An Old Disease with New Hope for the Future. Ca-A Cancer Journal for Clinicians, 2001, 51, 273-285.	329.8	36
11	Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma. Oncologist, 2001, 6, 17-21.	3.7	57
12	Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma. Bone Marrow Transplantation, 2001, 27, 663-666.	2.4	4
13	Multiple Myeloma. Clinical Obstetrics and Gynecology, 2002, 45, 928-938.	1.1	7
14	Myeloid cell factor–1 is a critical survival factor for multiple myeloma. Blood, 2002, 99, 1885-1893.	1.4	348
15	Arsenic Trioxide in Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2002, 8, 12-25.	2.0	37
16	Thalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma. Pharmacotherapy, 2002, 22, 1019-1028.	2.6	5
17	Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2). Journal of Cellular Physiology, 2002, 193, 42-54.	4.1	23
18	Bone marrow angiogenesis in multiple myeloma: effect of therapy. British Journal of Haematology, 2002, 119, 665-671.	2.5	48
19	Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia, 2002, 16, 1835-1837.	7.2	144

		PORT	
#	Article	IF	CITATIONS
20	Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia. Bone Marrow Transplantation, 2003, 32, 1065-1069.	2.4	6
21	IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene, 2003, 22, 1848-1859.	5.9	40
22	A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341,) Tj ETG Lymphoma and Myeloma, 2003, 4, 119-122.)q0 0 0 rg 2.1	BT /Overlock; 23
23	Cases from the Osler medical service at Johns Hopkins University. American Journal of Medicine, 2003, 114, 613-616.	1.5	1
24	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 21-33.	3.0	1,904
25	Bone marrow immunohistology of plasma cell neoplasms. Journal of Clinical Pathology, 2003, 56, 406-411.	2.0	38
26	Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood, 2003, 102, 2345-2350.	1.4	90
27	An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. British Journal of Cancer, 2004, 91, 1873-1879.	6.4	13
28	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplantation, 2004, 34, 235-239.	2.4	62
29	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia, 2004, 18, 624-627.	7.2	88
30	Clinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2004, 79, 867-874.	3.0	319
31	Multiple Myeloma. New England Journal of Medicine, 2004, 351, 1860-1873.	27.0	1,291
32	Cases from the Osler Medical Service at Johns Hopkins university. American Journal of Medicine, 2004, 117, 55-57.	1.5	1
33	Ki-67 Proliferation Index. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 8-13.	1.3	57
34	Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood, 2005, 106, 2276-2279.	1.4	213
35	Facteurs pronostiques du myélome utilisables en pratique couranteÂ: suivi sur dix ans de 148 malades A¢gés de plus de 55Âans. Revue Du Rhumatisme (Edition Francaise), 2005, 72, 1299-1305.	0.0	5
36	Factors useful for predicting survival of myeloma patients in everyday practice. A 10-year study of 148 patients older than 55 years. Joint Bone Spine, 2005, 72, 544-549.	1.6	3
37	Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 1371-1382.	3.0	210

#	Article	IF	CITATIONS
38	Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 2005, 23, 9219-9226.	1.6	402
39	Conventional therapy and approach to management. Best Practice and Research in Clinical Haematology, 2005, 18, 585-601.	1.7	6
40	In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1921-1931.	1.3	11
41	Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone, 2006, 39, 369-376.	2.9	26
42	β2-Microglobulin Promotes the Growth of Human Renal Cell Carcinoma through the Activation of the Protein Kinase A, Cyclic AMP–Responsive Element-Binding Protein, and Vascular Endothelial Growth Factor Axis. Clinical Cancer Research, 2006, 12, 7294-7305.	7.0	67
43	Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Human Pathology, 2007, 38, 1779-1787.	2.0	55
44	Targeting β2-Microglobulin Mediated Signaling as a Novel Therapeutic Approach for Human Renal Cell Carcinoma. Journal of Urology, 2007, 178, 292-300.	0.4	38
45	Relevant prognostic features of multiple myeloma and the new International Staging System. Leukemia and Lymphoma, 2007, 48, 458-468.	1.3	11
46	FISH panels for hematologic malignancies. Cytogenetic and Genome Research, 2007, 118, 284-296.	1.1	41
47	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 2007, 136, 393-399.	2.5	63
48	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. British Journal of Haematology, 2008, 141, 205-211.	2.5	20
49	Cellular immunotherapy for multiple myeloma. Best Practice and Research in Clinical Haematology, 2008, 21, 559-577.	1.7	18
50	Modern Treatment Options for Elderly Patients with Multiple Myeloma. Onkologie, 2008, 31, 10-10.	0.8	0
51	Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. European Journal of Haematology, 2009, 83, 528-534.	2.2	4
52	Multiple Myeloma. Current Problems in Cancer, 2009, 33, 7-64.	2.0	64
53	The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review. Cancer Treatment Reviews, 2009, 35, 425-430.	7.7	35
54	A novel role of HLA class I in the pathology of medulloblastoma. Journal of Translational Medicine, 2009, 7, 59.	4.4	19
55	PI3K/p110 \hat{i} is a novel therapeutic target in multiple myeloma. Blood, 2010, 116, 1460-1468.	1.4	177

#	Article	IF	Citations
56	Small Cell Tumors of Bone. Advances in Anatomic Pathology, 2010, 17, 1-11.	4.3	38
57	An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. American Journal of Hematology, 2010, 85, 752-756.	4.1	16
58	Ocular manifestations of multiple myeloma: Three cases and a review of the literature. Optometry - Journal of the American Optometric Association, 2011, 82, 224-230.	0.6	43
59	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, 2011, 117, 4696-4700.	1.4	285
60	Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood, 2011, 118, 2702-2707.	1.4	23
61	Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. American Journal of Hematology, 2011, 86, 25-30.	4.1	19
62	Conventional Cytogenetics and FISH [del13q, del17p, t(11;14), t(4;14)] Findings and Their Relationship with Other Risk Factors in Multiple Myeloma. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2011, 21, 203-209.	0.1	0
63	Multiple myeloma. Current Opinion in Supportive and Palliative Care, 2012, 6, 330-336.	1.3	17
64	The impact of frontline riskâ€adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group. European Journal of Haematology, 2012, 89, 136-144.	2.2	6
65	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leukemia Research, 2013, 37, 1070-1076.	0.8	15
66	Epigenetic inactivation of ADAMTS9 via promoter methylation in multiple myeloma. Molecular Medicine Reports, 2013, 7, 1055-1061.	2.4	12
67	β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 343-352.	1.7	53
68	A review of 74 patients with newly diagnosed multiple myeloma at a tertiary referral hospital in Nairobi, Kenya. Journal Africain Du Cancer, 2014, 6, 70-74.	0.1	3
69	Znaczenie bortezomibu w leczeniu szpiczaka plazmocytowego u pacjentów z ryzykiem cytogenetycznym. Acta Haematologica Polonica, 2014, 45, 247-257.	0.3	Ο
70	Relationship of P-Selectin Glycoprotein Ligand-1 to Prognosis in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 164-170.	0.4	6
71	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	12.8	38
72	Dickkopf-3 (DKK-3) obstructs VEGFR-2/Akt/mTOR signaling cascade by interacting of β2-microglobulin (β2M) in ovarian tumorigenesis. Cellular Signalling, 2015, 27, 2150-2159.	3.6	14
73	The evaluation of NT-proCNP, C-reactive protein and serum amyloid A protein concentration in patients with multiple myeloma undergoing stem cell transplantation. Leukemia Research, 2016, 47, 123-127.	0.8	1

CITATION REPORT

#	ARTICLE Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple	IF 12.8	Citations
75	Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica, 2017, 102, 785-795.	3.5	117
76	Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders. Cancer Genetics, 2018, 228-229, 184-196.	0.4	14
77	Globulin fraction and albumin: globulin ratio as a predictor of mortality in a South African multiple myeloma cohort. International Journal of Hematologic Oncology, 2020, 9, IJH27.	1.6	5
78	Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas. , 2004, , .		50
80	Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. Journal of Clinical Pathology, 2002, 55, 530-534.	2.0	52
81	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evidence, 2010, 4, 215.	4.7	18
83	Plasma Cell Proliferations. , 2004, , 364-378.		1
84	Bone Marrow. , 2006, , 493-532.		0
85	Clinical Evaluation of Some Biochemical Markers in Multiple Myeloma among Egyptian Patients. Journal of Medical Sciences (Faisalabad, Pakistan), 2007, 7, 942-951.	0.0	0
87	Multiple Myeloma and Related Disorders. , 2008, , 2323-2351.		1
88	Cytogenetics of Plasma Cell Neoplasms. , 2016, , 79-97.		0
89	Myeloma cells with asurophilic granulesan unusual morphological variant–case presentation. Journal of Medicine and Life, 2008, 1, 74-86.	1.3	6
90	Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma. Journal of Oncology, 2022, 2022, 1-7.	1.3	0
91	Bone marrow. , 0, , 813-942.		0
92	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. , 0, , 155-183.		0
94	Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life. Hematology, Transfusion and Cell Therapy, 2022, , .	0.2	1
95	Cross-sectional study of 100 cases of newly diagnosed plasma cell neoplasms in a tertiary care setup. Comparative Clinical Pathology, 0, , .	0.7	0

CITATION REPORT

ARTICLE

IF CITATIONS